Second demand front open and funded: a different kind of buyer is now paying, and management is resourcing it while it i
The model's full reasoning — Q4 2022 call → NO我们根据提供的财报电话会议记录来判断。问题问的是：管理层是否描述公司除了既有业务外，现在有第二个不同的需求来源，并且这个来源已经在支付真金白银，同时管理层正在积极投入资源支持这个第二战线，尽管它仍然是公司中明显较小的部分。 我们需要从记录中寻找证据。记录中提到了两个业务领域：MRD（微小残留病）和免疫医学（Immune Medicine）。MRD是clonoSEQ测试，针对血液癌症。免疫医学包括制药服务和药物发现。在免疫医学中，有与Genentech的合作，以及内部自身免疫项目。 关键点：第二个不同的需求来源是什么？可能是免疫医学中的制药服务？或者药物发现？但制药服务是向生物制药客户提供免疫受体数据，这似乎是既有的业务。而药物发现是与Genentech合作开发细胞疗法，这可能是新的。但问题要求“已经支付真金白银”且“仍然较小”。 在电话会议中，管理层提到“Pharma services had substantial growth of 67% versus 2021.” 这似乎是既有业务的一部分。而药物发现方面，与Genentech的合作有里程碑付款，但那是未来的。另外，内部自身免疫项目还在早期。 再仔细看：管理层说“In Immune Medicine, we made the strategic decision to focus our commercial and development efforts around pharma services and drug discovery.” 然后提到“Pharma services had substantial growth of 67% versus 2021.” 这可能是第二个战线？但制药服务是向制药公司销售数据服务，这可能是公司历史业务的一部分？实际上，Adaptive Biotechnologies最初是做免疫测序的，所以制药服务可能是其核心业务之一。而MRD是后来发展的。 但问题问的是“second, DIFFERENT FRONT OF DEMAND”相对于“established business that has historically paid it”。历史业务可能是免疫测序服务？但MRD也是其业务。实际上，公司重组为两个业务：MRD和免疫医学。免疫医学包括制药服务和药物发现。所以制药服务可能是历史业务的一部分，而MRD是新的？但MRD已经发展多年。 我们需要看管理层是否明确描述了一个新的、不同的需求来源，并且已经在产生收入，同时公司正在投入资源，但它仍然是较小的部分。 在电话会议中，管理层提到“In MRD, clonoSEQ clinical volumes grew 51% versus fiscal year 2021 supported by our fully trained sales team, which we nearly doubled during the year.” 所以MRD是增长引擎。而免疫医学中的制药服务也增长67%。但哪个是“second front”？ 或许“drug discovery”是新的，但还没有收入。而“pharma services”可能是既有的。 再读问题：要求“a second front, different in kind”相对于“historical mainstay”。历史主业务可能是免疫测序服务（pharma services）？但MRD也是其业务。实际上，公司最初是做免疫测序的，后来进入MRD。所以MRD可能是第二个战线？但MRD已经很大了，在2022年MRD收入占51%，免疫医学占49%，所以两者差不多。但问题要求“still a clearly smaller part”，所以如果MRD和免疫医学差不多，那就不符合。 但注意，在2023年指引中，MRD占55%，免疫医学占45%，所以MRD稍大，但免疫医学也不小。所以可能没有哪个是“clearly smaller”。 另外，管理层提到“In drug discovery, our partnership with Genentech had significant progress in both of our cell therapy programs.” 但那是未来的里程碑。 或许“T-Detect”是另一个？但管理层说“we made the decision in 2022, to delay commercialization efforts of T-Detect as a diagnostic test”，所以不是。 再仔细看，管理层在回答问题时提到“we have a lot of growth drivers other than DLBCL”，但那是MRD内部。 或许“community”是新的？但那是渠道。 我认为，管理层并没有明确描述一个“second front”是“already paying”且“still small”。相反，他们有两个业务部门，规模相当。而且，制药服务是既有业务，药物发现是未来的。 所以答案应该是NO。 但让我们再确认：在电话会议中，管理层提到“In Immune Medicine, we made the strategic decision to focus our commercial and development efforts around pharma services and drug discovery.” 然后说“Pharma services had substantial growth of 67% versus 2021.” 这可能是既有
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| FWONK | Formula One Group | Q1 2024 | 2024-05-08 | C+ |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| NC | NACCO Industries, Inc. | Q1 2024 | 2024-05-05 | C+ |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| TNET | TriNet Group, Inc. | Q1 2024 | 2024-04-26 | C |
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| LEGH | Legacy Housing Corporation | Q4 2023 | 2024-03-18 | C |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| OUT | Outfront Media Inc. | Q4 2023 | 2024-02-21 | C+ |
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| CHT | Chunghwa Telecom Co., Ltd. | Q4 2023 | 2024-01-30 | C |
| CPRT | Copart, Inc. | Q1 2024 | 2023-11-16 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| RVLV | Revolve Group, Inc. | Q3 2023 | 2023-11-01 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| GRBK | Green Brick Partners, Inc. | Q3 2023 | 2023-11-01 | B |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| FSBC | Five Star Bancorp | Q3 2023 | 2023-10-31 | B |
| ANGO | AngioDynamics, Inc. | Q1 2024 | 2023-10-04 | B |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| AEIS | Advanced Energy Industries, Inc. | Q2 2023 | 2023-08-03 | B |
| PERI | Perion Network Ltd. | Q2 2023 | 2023-08-02 | A |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| SLDP | Solid Power, Inc. | Q1 2023 | 2023-05-08 | C+ |
| TSN | Tyson Foods, Inc. | Q2 2023 | 2023-05-08 | D |
| ULCC | Frontier Group Holdings, Inc. | Q1 2023 | 2023-05-07 | C+ |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| AYI | Acuity Brands, Inc. | Q2 2023 | 2023-04-04 | C+ |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| ORGO | Organogenesis Holdings Inc. | Q4 2022 | 2023-03-01 | C |
| TWLO | Twilio Inc. | Q4 2022 | 2023-02-15 | D |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| ADM | Archer-Daniels-Midland Company | Q4 2022 | 2023-01-26 | C+ |
| WGO | Winnebago Industries, Inc. | Q1 2023 | 2022-12-16 | D |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| CMLS | Cumulus Media Inc. | Q3 2022 | 2022-10-28 | D |
| PKX | POSCO Holdings Inc. | Q3 2022 | 2022-10-24 | D |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| HLNE | Hamilton Lane Incorporated | Q1 2023 | 2022-08-02 | C+ |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| CNXC | Concentrix Corporation | Q1 2022 | 2022-03-30 | B |
| ZENV | Zenvia Inc. | Q4 2021 | 2022-03-17 | C+ |
| CDXC | ChromaDex Corporation | Q4 2021 | 2022-03-09 | C+ |
| VNDA | Vanda Pharmaceuticals Inc. | Q4 2021 | 2022-02-23 | F |
| AKAM | Akamai Technologies, Inc. | Q4 2021 | 2022-02-15 | B |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| FORM | FormFactor, Inc. | Q4 2021 | 2022-02-02 | B |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| MOMO | Hello Group Inc. | Q3 2021 | 2021-11-30 | D |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| BFI | BurgerFi International, Inc. | Q3 2021 | 2021-11-12 | C |
| ALHC | Alignment Healthcare, Inc. | Q3 2021 | 2021-11-06 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| CRS | Carpenter Technology Corporation | Q4 2021 | 2021-08-01 | A |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| DGX | Quest Diagnostics Incorporated | Q2 2021 | 2021-07-22 | B+ |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| SRDX | Surmodics, Inc. | Q3 2018 | 2018-08-06 | A |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| HPE | Hewlett Packard Enterprise Company | Q2 2018 | 2018-05-22 | B+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| FI | Fiserv, Inc. | Q4 2017 | 2018-02-27 | C |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| UNH | UnitedHealth Group Incorporated | Q4 2017 | 2018-01-16 | A |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| UAA | Under Armour, Inc. | Q3 2017 | 2017-10-31 | F |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| SBFG | SB Financial Group, Inc. | Q3 2017 | 2017-10-20 | A |
| STKL | SunOpta Inc. | Q2 2017 | 2017-08-09 | C+ |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| EPC | Edgewell Personal Care Company | Q3 2017 | 2017-08-08 | D |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| TPB | Turning Point Brands, Inc. | Q1 2017 | 2017-05-11 | B |
| KHC | The Kraft Heinz Company | Q1 2017 | 2017-05-03 | F |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
| MDLZ | Mondelez International, Inc. | Q4 2016 | 2017-02-07 | C |
| BDC | Belden Inc. | Q4 2016 | 2017-02-02 | B |
| AEHR | Aehr Test Systems | Q2 2017 | 2017-01-05 | F |
| LEE | Lee Enterprises, Incorporated | Q4 2016 | 2016-12-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| NTCT | NetScout Systems, Inc. | Q2 2017 | 2016-10-27 | D |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| CHDN | Churchill Downs Incorporated | Q2 2016 | 2016-08-04 | C+ |
| DUK | Duke Energy Corporation | Q2 2016 | 2016-08-04 | B |
| GEO | The GEO Group, Inc. | Q2 2016 | 2016-08-02 | B+ |
| CGNX | Cognex Corporation | Q2 2016 | 2016-08-01 | A |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| INGR | Ingredion Incorporated | Q1 2016 | 2016-05-01 | B+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
| ALE | ALLETE, Inc. | Q4 2015 | 2016-02-18 | B |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
FFWM · Q3 2021 → YESThe question is: Does management describe a SECOND, DIFFERENT FRONT OF DEMAND that is ALREADY PAYING IT REAL MONEY, and are they ACTIVELY PUTTING RESOURCES BEHIND that second front while it's still sm...YES The transcript shows management describing a second front in Texas (and soon Florida) that is genuinely different in kind from the historical California-Nevada-Hawaii focus. They explicitly frame it as expansion into new geographies with new customers and channels, not more of the same. Texas is already generating real revenue: the L PO group "started to put numbers on the board last quarter" with $100-150 million annual run rate expected in Q1, and builder finance is "officially up and running and beginning to bring in new business" with first loans funded. Equipment finance and C&I (43% of originations) are also contributing to the shift. Management is actively feeding it with resources: recruiting, opening offices in Irving and Plano, staffing up, and treating it as core to the transformation.
T · Q3 2018 → YESThe question is: Does management describe that the company now has a SECOND, DIFFERENT FRONT OF DEMAND that is ALREADY PAYING IT REAL MONEY, and is management ACTIVELY PUTTING RESOURCES BEHIND that se...NO The transcript does not meet the criteria for a clear second front. WarnerMedia is an acquisition just consolidated, which is explicitly excluded. Xandr is described as a new advertising platform launched in the quarter, with revenues up more than 30% partly due to the AppNexus acquisition, but it is tied to 7 billion in consolidated annual ad revenues and is not framed as a distinct, different front from the historical business. The advertising activity, while growing, is presented as an expansion of existing capabilities rather than a genuinely new source of demand. Management is actively investing in it, but it does not satisfy the requirement of being a clearly smaller, different front already paying real money in a distinct way.
AEHR · Q2 2017 → YESThe question is about whether management describes a second, different front of demand that's already paying real money, and they're actively putting resources behind it while it's still smaller. NO The transcript describes the FOX-XP system as a new, exciting market for optical devices, photonics, sensors, and automotive ICs, with initial shipments in engineering configuration and expectations for production shipments in Q3. However, it does not clearly establish that this second front is already generating real current revenue or paying 100% of the conditions: the production shipments are still prospective, the FOX-1P shipments are mentioned but not explicitly tied as the primary new front, and while resources are being invested, the evidence for immediate revenue from the distinct optical/photonics front is not sufficiently concrete to meet all three criteria simultaneously.